The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
| dc.contributor.author | Townsend, Elizabeth C. | |
| dc.contributor.author | Kelliher, Michelle A. | |
| dc.contributor.author | Roderick, Justine E. | |
| dc.contributor.author | Weinstock, David M. | |
| dc.date | 2022-08-11T08:09:20.000 | |
| dc.date.accessioned | 2022-08-23T16:26:59Z | |
| dc.date.available | 2022-08-23T16:26:59Z | |
| dc.date.issued | 2016-04-11 | |
| dc.date.submitted | 2017-04-20 | |
| dc.identifier.citation | Cancer Cell. 2016 Apr 11;29(4):574-86. doi: 10.1016/j.ccell.2016.03.008. <a href="https://doi.org/10.1016/j.ccell.2016.03.008">Link to article on publisher's site</a> | |
| dc.identifier.issn | 1535-6108 (Linking) | |
| dc.identifier.doi | 10.1016/j.ccell.2016.03.008 | |
| dc.identifier.pmid | 27070704 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/36679 | |
| dc.description | <p>Full author list omitted for brevity. For the full list of authors, see article.</p> | |
| dc.description.abstract | More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease. | |
| dc.language.iso | en_US | |
| dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27070704&dopt=Abstract">Link to Article in PubMed</a> | |
| dc.relation.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177991/ | |
| dc.subject | Cancer Biology | |
| dc.subject | Cell Biology | |
| dc.subject | Cellular and Molecular Physiology | |
| dc.title | The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice | |
| dc.type | Journal Article | |
| dc.source.journaltitle | Cancer cell | |
| dc.source.volume | 29 | |
| dc.source.issue | 4 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/metnet_pubs/48 | |
| dc.identifier.contextkey | 10048069 | |
| html.description.abstract | <p>More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.</p> | |
| dc.identifier.submissionpath | metnet_pubs/48 | |
| dc.contributor.department | UMass Metabolic Network | |
| dc.contributor.department | Department of Molecular, Cell and Cancer Biology | |
| dc.source.pages | 574-86 |
Files in this item
Name:
Publisher version